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Background: Despite limited evidence of efficacy, antibiotic treatment is still fre-
quently prescribed in dogs with uncomplicated acute diarrhea (AD).
Objective: To assess whether amoxicillin-clavulanic acid has a clinical benefit, an
effect on the fecal microbiome, and the proportion of amoxicillin-resistant Escherichia
coli in dogs with AD.
Animals: Sixteen dogs with AD of <3 days duration.
Methods: Prospective, placebo-controlled, double-blinded study. Clinical scores were
compared between client-owned dogs randomly assigned to an antibiotic (AG) or a
placebo (PG) group. The intestinal microbiome was analyzed using quantitative PCR
assays. Amoxicillin-resistant fecal E. coli were assessed semiquantitatively with micro-
biological methods.
Results: There was no difference in clinical recovery between treated dogs or con-
trols (CADS index day 10: AG group median: 2 (range: 1-3; CI [1.4; 2.6]); PG group
median: 1.6 (range: 1-3; CI [1.1; 2.4]); P > .99). All dogs gained normal clinical scores
(CADS index ≤3) after 1 to 6 days (median 2 days) after presentation. There was no
significant difference in the fecal dysbiosis index (during treatment: AG mean −2.6
(SD 3.0; CI [−5.1; 0.0]); PG mean −0.8 (SD 4.0; CI [−4.2; 2.5]; P > .99) or its bacterial
taxa. The proportion of resistant fecal E. coli increased (to median: 100%; range: 35%-
100%) during treatment with amoxicillin-clavulanic acid and was still increased
(median: 10%; range 2%-67%) 3 weeks after treatment, both of which were
Abbreviations: AG, antibiotic group; AHDS, acute hemorrhagic diarrhea syndrome; CADS-Index, Canine Acute Diarrhea Severity Index; PG, placebo group.
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significantly higher proportions than in the placebo group for both time points (during
treatment AG median 100% versus PG median 0.2% (P < .001); after treatment AG
median 10% versus PG median 0.0% (P = .002)).
Conclusions and Clinical Importance: Our study suggests that treatment with
amoxicillin-clavulanic acid confers no clinical benefit to dogs with AD, but predis-
poses the development of amoxicillin-resistant E. coli, which persist for as long as
3 weeks after treatment. These findings support international guideline recommenda-
tions that dogs with diarrhea should not be treated with antimicrobials unless there
are signs of sepsis.
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1 | INTRODUCTION
Diarrhea is a common reason for dogs being presented for veterinary
care with approximately 7% of the dogs presented in small animal prac-
tice showing diarrhea.1 Uncomplicated acute diarrhea (AD) in dogs is
most frequently associated with dietary indiscretion, adverse reactions
to food, endoparasites, or transient uncomplicated bacterial/viral infec-
tions.2-6 In many cases the etiology cannot be identified. This is usually
not a problem, because clinical signs typically resolve spontaneously and
usually do not recur.2,4,7-9 International guidelines recommend that in
dogs with diarrhea, antimicrobials should only be administered to dogs
manifesting systemic signs of illness.10-14 Despite these recommenda-
tions, it is common that dogs with AD receive an untargeted, short-term
antibiotic course as first-line medication. Two surveys including 11 060
and 371 dogs performed in Europe showed that between 63% and 71%
of dogs with AD were treated with antimicrobials, respectively.15,16 Our
study group previously evaluated the effect of amoxicillin-clavulanic acid
in dogs with acute hemorrhagic diarrhea syndrome (AHRD) without signs
of sepsis, and were unable to show a clinical benefit of antibiotic ther-
apy.17,18 A second study in dogs with AHDS revealed that the additional
application of metronidazole to amoxicillin-clavulanic acid did not
improve the clinical outcome.18
Antibiotic treatment can lead to various negative short-term
effects, such as vomiting, diarrhea, and anorexia.19,20 Data from
human medicine suggest that dysbiosis induced by antimicrobials
is associated with an increased risk for developing asthma, post-
infectious irritable bowel syndrome and chronic enteropathies such as
Crohn's disease.21-25 Antibiotics cause prolonged intestinal dysbiosis
and lead to changes in the microbial metabolism pathways in healthy
dogs and humans.26-29 Disruption of the intestinal microbiota as a
consequence of antibiotic use can lead to life-threatening Clostridiodes
difficile infections in humans.30 Furthermore, antibiotic treatment
leads to advantages in growth for resistant bacteria and provokes the
development of new resistance mechanisms.31-35
Although antibiotics have been routinely used in dogs with uncom-
plicated AD over decades, evidence-based studies documenting any clin-
ical benefit of antibiotic treatment in dogs are sparse36 and do not exist
for potentiated penicillins, which are frequently used as first-line antibi-
otic treatment. Thus, the aims of this study were to evaluate the clinical
benefit of amoxicillin-clavulanic acid, to evaluate the effect of the
amoxicillin-clavulanic acid on the intestinal microbiome, and the propor-
tions of resistant fecal Escherichia coli in dogs with uncomplicated AD.
2 | MATERIALS AND METHODS
2.1 | Animals
This study was designed as a prospective, double-blinded, random-
ized, placebo-controlled, trial. The study design was approved by the
ethical committee of the Centre for Clinical Veterinary Medicine
Ludwig-Maximilians-University, Munich (reference 68-19-05-2016).
An informed client consent form was signed by all owners. The dogs
were recruited between July 2016 and January 2018 by the same vet-
erinarian (MW) across 4 small animal clinics in Munich, Germany. The
randomization list was formed before start of the study through a
third person using a research randomizer available on the following
website: https://www.graphpad.com/quickcalcs/randomize1.cfm.
Dogs of either sex with acute nonhemorrhagic diarrhea between
5 and 40 kg bodyweight, and of at least 9 months of age were
enrolled into this study. Only dogs with a fecal consistency score of at
least 2 on the CADS-Index (Table 1) and a duration of gastrointestinal
symptoms of <3 days were enrolled. Exclusion criteria were the fol-
lowing: treatment with an antimicrobial within 30 days or treatment
with an anti-inflammatory drug within 7 days before presentation,
blood in feces, any signs of systemic inflammation (eg, rectal tem-
perature > 39.0C [102.2 F]), severe illness (eg, lethargic mental sta-
tus, moderate to severe abdominal pain), or significant dehydration
prompting hospitalization. These exclusion criteria were chosen to
define the disease as “uncomplicated,” thus only dogs that could be
treated as outpatients, were included.
The histories of all dogs were recorded in a standardized method
with specific questions regarding stress-related factors, diet, dietary
changes, feeding of treats, chronic illnesses, other diseases in the last
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months before presentation, drug administration and timing of any
past diarrheic episode.
Diagnostic work-up in all dogs before inclusion consisted of a blood
count, serum chemistry profile (urea nitrogen, creatinine, SDMA, sodium,
chloride, potassium, phosphate, total bilirubin, ALT, ALP, gamma-GT,
AST, GLDH, total protein, albumin, globulin, glucose, alpha-amylase,
lipase, cholesterol, fructosamine, creatine kinase, LDH, calcium, magne-
sium, triglycerides), and a fecal flotation.
2.2 | Treatment
All dogs were randomly assigned to the antibiotic (AG) or the placebo
group (PG) bymeans of a computer-generated schedule. Dogs allocated to
AG group received capsules filled with amoxicillin-clavulanic acid per os at
12.5 to 25 mg/kg q12h and dogs allocated to PG group received capsules
filled only with the carrier substance lactose (300 mg per capsule) per os
q12h. Duration of treatment was 7 days in either group. For blinding pur-
poses, the capsules were indistinguishable between the 2 groups. Every
dog received a certain number of capsules according to the predefined
weight group. To ensure standardization, all dogs were treated with the
same symptomatic treatment: maropitant (Cerenia, Zoetis GmbH, Berlin,
Germany) as an antiemetic (1 mg/kg given once subcutaneously) andmet-
amizole (Novaminsulfon, Ratiopharm, Ulm, Germany) as an analgesic
(30 mg/kg per os q8h for 2 days). All dogs were fed with the same gastro-
intestinal diet (Royal CaninGastrointestinal wet or dry) for 7 days.
2.3 | Evaluation of treatment efficacy
Particular attention was paid to the clinical improvement over time. At
the day of presentation and inclusion into the study, defined as day 0, all
dogs were evaluated with the canine acute diarrhea severity (CADS)
index (Table 1). Every following day, from day 1 to day 10, the score was
reassessed by the owner and documented in a diary. If dogs defecated
more than once per day, the fecal consistency score was calculated as
the average of all defecations of that day. To evaluate the difference
between groups, the CADS-Index of each day was compared between
AG and PG. Moreover, the time to normalization of fecal consistency
(score 0 or 1) was documented in every individual dog.
2.4 | Sample collection
Naturally passed fecal samples from each dog were collected by the
clinician on day 0 before starting the treatment, and by the owner on
day 6 and day 30. Samples for fecal flotation (performed on days
0 and 6) and bacterial culture (performed on days 0, 6, and 30) were
processed within a few hours after collection (ie, <6 hours), whereas
aliquots for microbiome analysis (days 0, 6, and 30) were frozen at
−80C. These samples were sent for microbiome analysis on dry ice
to the Gastrointestinal Laboratory at Texas A&M University.
2.5 | Microbiome analysis
2.5.1 | DNA extraction
DNA was extracted from an aliquot of 100 mg of each fecal sample
using a MoBio Power soil DNA isolation kit (MoBio Laboratories)
according to manufacturer's instructions. The bead-beating step was
performed on a homogenizer (FastPrep-24; MP Biomedicals, Santa
Ana, California) for 60 seconds at a speed of 4 m/s. Fecal DNA was
stored at −80C until further evaluation.
2.6 | Quantitative PCR (qPCR)
For chosen bacterial taxa (ie, Faecalibacterium spp., Turicibacter spp.,
Streptococcus spp., E. coli, Blautia spp., Fusobacterium spp., and Clos-
tridium hiranonis) and total bacteria, which are known to be altered in
dogs with gastrointestinal disease, individual qPCR assays were per-
formed and results used to calculate the recently described dysbiosis
index (DI).37 The method, including the oligonucleotide sequence of the
primers and the annealing temperatures were described elsewhere previ-
ously.37 A DI <0 reflects normobiosis, whereas a DI ≥2 dysbiosis, and
values between 0 and 2 are considered to be equivocal. The abundances
of Clostridium perfringens 16S rRNA gene, C. perfringens enterotoxin gene,
C. perfringens NetF gene, C. difficile 16S rRNA gene, and C. jejuni gene in
feces were analyzed by qPCR assays using the published oligonucleotide
primers and assays.38-41 PCR conditions were 95C for 20 seconds,
40 cycles at 95C for 5 seconds, and 10 seconds at the optimized
annealing temperature. For probe-based assays, the mastermix contained
10 μL of TaqMan reaction mixtures consisting of 5 μL of TaqMan Fast
Universal PCR master mix (2×), No AmpErase UNG (Applied Biosystems),
0.4 μL of each primer (concentration: 400 nM), 0.2 μL of the probe (con-
centration: 200 nM), 1 μL of 1% bovine serum albumin (BSA, concentra-
tion: 0.1%), 1 μL of water, and 2 μL of DNA (1:10 or 1:100 dilution). For
SYBR-based assays, PCR procedures were performed at 95C for
2 minutes, 40 cycles at 95C for 5 seconds, and 10 seconds at the opti-
mized annealing temperature with 10 μL of SYBR-based reaction mix-
tures consisted of 5 μL of SsoFast EvaGreen supermix (Biorad
TABLE 1 Scoring system of the
Canine Acute Diarrhea Severity Index
Activity 0: Normal 1: Mild 2: Moderate 3: Severely decreased
Appetite 0: Normal 1: Mild 2: Moderate 3: Severely decreased
Vomiting 0: normal 1: 1×/d 2:2-3×/d 3: > 3×/d
Fecal consistency 0: Normal 1: Moist, shaped 2: Pasty 3: Watery diarrhea
Frequency of defecation 0: Normal 1:2-3×/d 2:4-5×/d 3: > 5×/d
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Laboratories), 0.4 μL of each primer (concentration: 400 nM), 1 μL of 1%
BSA (concentration: 0.1%), 1.6 μL of water, and 2 μL of DNA (1:10 or
1:100 dilution). The oligonucleotide sequences of the primers and pro-
bes, and the annealing temperatures can be found in Table S1.
2.7 | Evaluation of the proportion of resistant
fecal E. coli
One gram of feces was placed into a test tube and mixed with 9 mL of
phosphate buffered saline (PBS; pH = 7.0). The mixture was homoge-
nized for 5 minutes. The material was used in a 1:10 dilution series
with PBS. Each 100-μl aliquot of the dilutions was plated onto
MacConkey-Agar (MAC) plates containing no antibiotic and onto
MAC plates mixed with ampicillin at a concentration of 32 μg/mL
(MAC + AMP). This concentration was used based on the guidelines
of the Clinical & Laboratory Standards Institute. Isolates that grew on
MAC + AMP were considered to be cross-resistant to ampicillin and
amoxicillin. Plates were incubated for 20 to 24 hours at 37C, and
E. coli isolates from both plates were identified by Matrix Assisted
Laser Desorption Ionization Time-of-Flight Mass Spectrometry
(Bruker Microflex LT). The percentage of ampicillin-resistant E. coli
was calculated as follows: (number of isolates on MAC + AMP/
number of isolates on MAC) × 100. The detection limit was set to
100 cfu/g. Resistant bacteria growing on the MAC + AMP were puri-
fied, and resistance of the isolates was confirmed by ampicillin (which
is cross-resistant to amoxicillin) disk diffusion susceptibility testing.
2.8 | Statistical analyses
Power analysis determined that in order to detect a clinically relevant
difference of 2 points in the CADS-Index at day 3 between the AG
and the PG, at least 8 dogs per group had to be included (with an esti-
mated SD of 1.5, power of 80% and P < .05).
Statistical analyses were conducted with GraphPad Prism
(GraphPad Prism c7.0, GraphPad Software, San Diego, California).
Data were evaluated for normality by the D'Agonisto-Pearson omni-
bus normality test. Differences in laboratory variables between groups
were analyzed by unpaired t test with Welch's correction or the
Mann-Whitney U test. To avoid inflated type I error, Bonferroni cor-
rection was used. Differences in sex and last diarrheic event were
evaluated with the Mann-Whitney U test and the differences in the
variables age, bodyweight, duration of diarrhea, diet change, and
stressful event using an unpaired t test. The course of the CADS-
Index and those of individual variables, the DI, the included taxa
(Faecalibacterium spp., Turicibacter spp., Streptococcus spp., E. coli,
Blautia spp., Fusobacterium spp., and C. hiranonis), total bacteria,
C. perfringens, C. perfringens enterotoxin gene, C. perfringens NetF
toxin, and C. difficile were analyzed by Kruskal-Wallis test or ordinary
ANOVA-analysis (depending on normality) with Dunn's test for multi-
ple comparison as a posttest for comparison between the 2 groups.
The difference in the time to normalization of fecal consistency was
evaluated with the Mann-Whitney U test. Percentage of resistant
TABLE 2 Baseline variables in dogs with diarrhea
AG (n = 8) PG (n = 8) P-value
Sex 4 male, 4 female 3 male, 5 female .88
Neutered/entire 5/3 2/6 .62
Breeds Mixed breed (1), Australian Shepherd (1), Entlebucher Mountain
Dog (1), German Hunting Terrier (1), Jack Russell Terrier (1),
Maltese Dog (1), Miniature Poodle (1), Pug (1)
Mixed breed (3), Elo (1), Barbet (1), Labrador
Retriever (1), Miniature Pinscher (1),
Miniature Poodle (1)
Median Range Median Range
Bodyweight (kg) 9.1 5.6-25.0 14.9 7.2-29.5 .21
Age (years) 7.5 1.0-11.0 5 1.0-11.0 .30
Abbreviations: AG, amoxicillin-clavulanic acid group; PG, placebo group.
F IGURE 1 Clinical evaluation of clinical signs according to the
canine acute diarrhea severity index (CADS index). The index includes
the variables activity, appetite, vomiting (times/day), fecal
consistency, and frequency of defecation (times/day). Each variable is
scored from 0 to 3, and the sum of scores yields a total cumulative
score. Dots show the mean, error bars show SD. No difference in the
CADS-Index on any day of the study period could be observed
between AG and PG (P > .99). AG, amoxicillin-clavulanic acid group;
PG, placebo group
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E. coli were compared between the groups by a Mann-Whitney U test
and within group between different time points with the Wilcoxon
matched-pairs signed rank test. The adjusted significance level after
Bonferroni correction for the laboratory variables was set at 0:0536
(= .0014). For all other statistical tests, the significance level was set
at P = .05.
3 | RESULTS
3.1 | Study population
A total of 16 dogs fulfilled the inclusion criteria. Dogs were ran-
domly assigned into the AG group (n = 8) and the PG group (n = 8).
Age, sex, bodyweight, and prevalence of breeds were not different
between the groups (Table 2). Median duration of diarrhea until
presentation was 32 (range 4-72) hours. Eleven of 16 dogs (69%)
showed additional vomiting at least 1 time. Baseline laboratory var-
iables of all dogs are presented in Table S2 showing no statistically
significant differences between the groups after Bonferroni correc-
tion. Five of 16 owners (31%) described a stressful event for the
dog in the last few days before presentation. One of 16 dogs (6%)
was fed with a raw-meat diet. Six of 16 dogs (37%) received table
scraps as a treat and a dietary change had been made in 5 of
16 dogs (31%) before the diarrheic event. Other acute diseases in
the last 30 days were documented in 5 of 16 dogs (31%) and
chronic diseases in 6 of 16 dogs (37%). One of 16 dogs received
levothyroxine as long-term medication. Eleven of 16 dogs (69%)
had a history of acute diarrheic events previously; however, the
median interval to the last event was 2 (range 0.5-10.0) months. No
significant differences in variables from the dogs’ histories between
groups were observed.
3.2 | Treatment efficacy
No statistically significant difference in the CADS-Index (P > .99), and
more specifically in fecal consistency (P > .99) on any day of the study
period could be observed between the AG and the PG (Figure 1). On
day 0, the day of inclusion, dogs were presented with a median
CADS-Index of 7 (range 4-11; CI [4.9; 9.1]) in the AG group and
6 (range 5-11; CI [6.3; 9.5]) in the PG group. There was no significant
difference in the CADS-Index between groups on day 0 (P > .99). On
the last day of the study period (day 10) there was no significant dif-
ference of the CADS-Index between the AG group (median: 2 (range:
1-3; CI [1.4; 2.6]) and the PG group (median: 1.6 (range: 1-3; CI [1.1;
2.4])) (P > .99): 2 dogs of the AG group and 1 dog of the PG group still
had pasty feces upon conclusion of the study. All dogs in both groups
reached normal clinical scores (CADS-Index ≤3) 1 to 6 days (median
2 days) after presentation.
Regarding presence and frequency of vomiting, fecal frequency,
activity, and appetite there was no significant difference between
groups on all days of the study period.
F IGURE 2 The dysbiosis index (DI) in dogs with diarrhea over
time. A DI < 0 indicates normobiosis, whereas a DI ≥ 2 indicates
dysbiosis. Dots show the mean, error bars show SD. There was no
difference of the DI between the groups at any time point (P > .99).
AG = amoxicillin-clavulanic acid group. PG = placebo group
TABLE 3 Dysbiosis index and the investigated phyla in dogs with diarrhea
AG PG
Day 0 Day 6 Day 30 Day 0 Day 6 Day 30
Dysbiosis index −1.4 (3.3) −2.6 (3.0) −0.8 (2.4) −0.4 (3.2) −0.8 (4.0) 0.1 (3.3)
Total bacteria 10.8 (0.3) 10.8 (0.3) 10.8 (0.2) 10.8 (0.2) 10.7 (0.2) 10.5 (0.3)
Faecalibacterium spp. 5.1 (1.0) 5.2 (1.3) 6.0 (1.4) 4.7 (1.3) 4.6 (1.5) 5.1 (1.2)
Turicibacter spp. 6.1 (1.3) 5.7 (1.2) 5.6 (1.0) 5.8 (1.1) 5.8 (1.4) 6.4 (1.1)
Streptococcus spp. 4.4 (1.8) 3.8 (1.3) 5.2 (2.0) 4.6 (1.9) 4.5 (1.5) 5.5 (1.9)
Escherichia coli 6.7 (1.8) 5.9 (1.8) 6.0 (2.1) 7.1 (1.6) 6.4 (2.2) 6.7 (1.0)
Blautia spp. 10.1 (0.8) 10.4 (0.5) 10.4 (0.5) 10.0 (0.9) 9.9 (1.1) 9.9 (1.0)
Fusobacterium spp. 9.5 (1.1) 9.7 (0.5) 8.7 (1.5) 8.9 (0.8) 8.8 (1.1) 7.7 (1.1)
Clostridium hiranonis 4.9 (3.0) 5.0 (2.8) 5.0 (3.1) 4.8 (3.0) 5.1 (2.4) 5.2 (2.5)
Note: Values represent mean (SD) log DNA/g feces.
Abbreviations: AG, amoxicillin-clavulanic acid group; PG, placebo group.
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The median time to normalization of fecal consistency was not
statistically different between the AG (median: 1 day, range: 1-6 days;
CI [0.3; 2.3]) and PG (median: 2 days, range 1-3 days; CI [1.2; 2.6]).
3.3 | Microbiome analysis
There was no statistically significant difference of the DI (day 0 AG
mean − 1,4 (SD 3.3; CI [−4.2; 1.3]); PG mean − 0.4 (SD 3.2; CI [−3.1;
2.2]); P > .99; day 6 AG mean − 2.6 (SD 3.0; CI [−5.1; 0.0]); PG mean
− 0.8 (SD 4.0; CI [−4.2; 2.5]; P > .99; day 30 AG mean − 0.8 (SD 2.4;
CI [−2.8; 1.2]); PG mean 0.1 (SD 3.3; CI [−2.7; 2.8]); P > .99) and
investigated taxa between the groups at any time point (Figure 2,
Table 3). An increased DI (> 2) was found in 7 dogs (AG: 3/8; PG: 4/8)
for at least at 1 time point. Bacterial species considered as potentially
enteropathogenic were evaluated in both groups. However, there was
no significant difference in the fecal profiles for C. perfringens.
C. perfringens enterotoxin gene was decreased on day 6 compared to
day 0 with a rebound on day 30 in the AG without reaching signifi-
cance (Figure 3). The C. perfringens NetF gene was found in feces of
2 dogs (1 dog on day 0 and 1 dog on day 30). In 3/8 dogs in the AG
group on day 6 and in 1/8 dogs of the PG group on day 0 and
6, C. difficile strains could be detected, but there was no significant
difference between groups at either time point. Campylobacter jejuni
was not found in any sample.
3.4 | Evaluation of percentage of resistant
fecal E. coli
E. coli colonies were found in 44 of total 48 samples (92%). Forty of
these 44 samples had at least 100 cfu/g resistant colonies. In 4 sam-
ples, resistant E. coli isolates were not detected. One of this 4 samples
were cultured from a dog of the AG and 3 from dogs of the PG on
day 30. On day 0, before the antibiotic treatment was started, the
median percentage of ampicillin-resistant E. coli was 0.2% (range 0%-
4%) in the AG group and 0.1% (range 0%-9%) in the PG group with no
significant difference between groups (P = .94). On day 6, the percent-
age of ampicillin-resistant colonies was significantly higher in the AG
than in the PG group. The median percentage of ampicillin-resistant
F IGURE 3 Abundance of C. perfringens (A) and C. perfringens
enterotoxin gene (B). Dots show the mean, error bars show the SD. No
difference in the fecal profiles for C. perfringens could be observed
between the groups at any time point. AG, amoxicillin-clavulanic acid
group; PG, placebo group
F IGURE 4 Percentages of amoxicillin-resistant E. coli in diarrheic dogs treated with amoxicillin-clavulanic acid (A) or placebo (B). Circles and
filled in circles represent individual values for dogs of AG and PG, respectively. Bars show the median. *P < .05. A higher percentage of resistant
E. coli could be observed in the AG group compared to the PG on day 6 (P < .001) during and on day 30 (P = .002) 3 weeks after antibiotic
treatment. AG, amoxicillin-clavulanic acid group; PG, placebo group
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colonies rose to 100% in the AG group (range 35%-100%), in the PG
group the median was 0.2% (range 0%-10%, P < .001). On day
30, 3 weeks after discontinuing antibiotic treatment, there was still a
significant higher percentage of resistant E. coli in the AG group
(median 10%; range 2%-67%) than in the PG group (median 0%; range
0%-4%; P = .002; Figure 4).
4 | DISCUSSION
In this prospective, double-blinded, placebo-controlled study, clinical
improvement of dogs with acute uncomplicated diarrhea was compared
between dogs only treated with symptomatic treatment and those also
treated with amoxicillin-clavulanic acid. There was no statistically signifi-
cant difference in the clinical course between groups at any time point.
Oral treatment with amoxicillin-clavulanic acid led to a significant
increase of resistant E. coli isolates, but based on the DI, did not result in
a significantly more prolonged dysbiosis compared with the PG.
The absence of a beneficial clinical effect of amoxicillin-clavulanic
acid treatment in dogs with uncomplicated AD is an important finding
for clinicians, who routinely manage these cases on a daily basis.
Amoxicillin-clavulanic acid was chosen because beta-lactam antibi-
otics are the most frequently used antimicrobials in gastrointestinal
disease in dogs and cats.1,16
It is estimated that currently more than half of dogs with AD are
treated with antimicrobials, although a clinical benefit has not been
proven so far.1,16 This treatment approach is primarily based on the
subjective impression of a more rapid clinical improvement with anti-
biotics. Furthermore, for several reasons there is a low threshold for
using antibiotics in veterinary practice including diagnostic uncer-
tainty, fear of clinical deterioration, time pressure, client expectations,
and the general tradition to use antibiotics in dogs with diarrhea.42
This study should serve as a basis documenting that routine antibiotic
treatment is not advantageous for dogs with uncomplicated AD. It
underlines the recommendation in the ACVIM Consensus Statement
of 2011 to administer antimicrobials only to dogs and cats with diar-
rhea that manifest systemic signs of illness (ACVIM consensus entero-
pathogenic bacteria).10,43
No obvious negative short-term clinical adverse effects of
amoxicillin-clavulanic acid treatment could be observed in this study,
although it has been shown that administration of various antibiotics
to healthy dogs and cats can cause diarrhea, which rapidly resolves
after discontinuation of the antimicrobials. A current meta-analysis in
humans showed that about 10% of individuals with acute infectious
enteritis develop chronic intestinal problems later in life, and treat-
ment with antibiotics during the acute phase increases this risk.44 Fur-
ther investigations are needed to evaluate the long-term effects of
antibiotics in dogs with AD on general health and more specifically on
gut health.
The present study revealed that the most significant clinical
improvement was observed within the first 2 days after the onset of
clinical signs. This corresponds with findings of previous studies in
which the duration of diarrhea was reported to be as 1 to 3 days,8 or
less than 2 days.9 Dogs stayed clinically stable until the endpoint of
the study (day 10). Three of 16 dogs still had pasty feces on day 10.
This is in contradiction with a study describing a complete resolution
of diarrhea in all dogs within a few days.4,9 The different study design
(retrospective versus prospective) might represent 1 explanation for a
different assessment of the dog's status by the owner. In this context,
the cause for the clinical changes are of interest. Around one third of
the dogs had a stressful event, received table scraps, or underwent a
diet change before presentation. These findings correspond with find-
ings of previous studies, in which diet change and receiving treats
were described as risk factors for acute gastrointestinal symptoms.2,9
Based on the CADS-Index, dogs in both groups were defined as
moderately diseased. No clinically relevant changes on CBC or serum
biochemistry profile could be observed in any dog. These facts can be
explained by the exclusion of dogs with severe disease activity. This
dog population was selected, because it was specifically aimed to
assess if the typical case with uncomplicated diarrhea, which is seen
by practitioners on a daily basis, benefits from antibiotic treatment.
A DI, based on the 7 bacterial taxa Faecalibacterium, Turicibacter,
Streptococcus, E. coli, Blautia, Fusobacterium, and C. hiranonis and total
bacteria, was determined in all dogs based on fecal samples collected
on days 0, 6, and 30. This index was developed to quantify intestinal
dysbiosis in dogs. Several studies revealed intestinal dysbiosis in dogs
with AD and chronic enteropathies. In the present study, the median
dysbiosis index for each treatment group was not significantly
increased on day 0 in comparison with the reference range of the DI
in either group. This means that in the present study population of
dogs with uncomplicated AD, a significant dysbiosis could not be
documented based on the DI. This finding suggests that in mild forms
of AD the intestinal microbiome is not profoundly altered, which is in
contrast to the significant dysbiosis documented in dogs with chronic
enteropathies.45
Moreover, in the present study the treatment with amoxicillin-
clavulanic acid did not result in significant alterations in the DI or its
included taxa during as well as 3 weeks after the treatment. In con-
trast, another study described a significant alteration in the intestinal
microbiome in healthy dogs receiving amoxicillin.26-28 This discrep-
ancy could partially be explained because the cited study was per-
formed in healthy dogs, no control group for comparison of intestinal
microbiota changes was used, and a huge interpatient variability
was seen.
Recent investigations showed a profound effect of metronidazole
and tylosin on the microbiota. Tylosin significantly increased the DI during
treatment, and the abundance of Faecalibacterium was significantly
decreased after treatment.46 Also, treatment with metronidazole in dogs
leads to significant alterations in the intestinal microbiomewith decreased
abundances of the taxa Bacteroidaceae, Clostridiaceae, Fusobacteriaceae,
Lachnospiraceae, Ruminococcaceae, Turicibacteraceae, and Veillonellaceae
and increased abundances of Bifidobacteriaceae, Enterobacteriaceae,
Enterococcaceae, and Streptococcaceae.27
Based on the discrepancy of the microbiome alterations between
different antimicrobials, further investigations comparing the effect of
several antimicrobials on a defined population of dogs in 1 study
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would be desirable. One possible explanation for the lack of detect-
able dysbiosis in the AG is that the diarrheal process itself could have
reduced exposure of the gut microbiome to amoxicillin-clavulanic
acid; however, given the significant effect of antibiotic treatment on
amoxicillin resistance in E. coli, this possibility can be eliminated. In
contrast, in a study of healthy cats treated with amoxicillin-clavulanic
acid, the cats showed significant changes of the intestinal
microbiome,19 consequently species-dependent differences might be
possible.
C. perfringens can be found as a normal component of the intesti-
nal tract in healthy dogs. However, clostridial overgrowth plays an
important role in dogs with acute hemorrhagic diarrhea syndrome
(AHDS).47 Applying a quantitative PCR protocol, no significant differ-
ences in the abundance of C. perfringens in dogs of both treatment
groups on day 0 were detected. A decrease in both C. perfringens and
its enterotoxin-encoding strains on day 6 and a rebound on day
30 was observed in the AG group; however, without reaching signifi-
cance in comparison with the PG. Similar findings were shown in a cat
population also treated with amoxicillin-clavulanic acid.19 Thus,
amoxicillin-clavulanic acid appears to be effective in reducing the
number of clostridial strains. However, this effect is only short-lived,
because the abundance of C. perfringens has been reported to return
to baseline values a few weeks after discontinuing antimicrobial treat-
ment.48 A correlation of clinical signs with the abundance of
C. perfringens strains was not observed in the present study. The
C. perfringens NetF toxin gene was found in 2 dogs (corresponding to
4% of the fecal samples) and therefore we conclude it is unlikely to
have played a substantial role in causing diarrhea in the present study
population. In previous studies, a higher abundance of C. perfringens,
encoding for NetF toxin gene was detected in dogs AHDS,49,50 but
C. perfringens encoding for NetF toxin gene decreased within a few
days even without the use of antibiotics.51 A recent paper showed a
prevalence of 48.1% in dogs with acute hemorrhagic diarrhea whereas
only 12.1% of the healthy dogs carried the NetF gene.52
C. difficile is known to induce pseudomembranous colitis and is
associated with significant morbidity and mortality in humans.53 Sev-
eral studies showed that antibiotic use and more specifically the appli-
cation of penicillin, is a major risk factor for the development of
C. difficile infections.54,55 The role of C. difficile in the etiology of
canine diarrhea is still unclear. However, some studies showed a
slightly higher prevalence of C. difficile in dogs with diarrhea compared
to healthy dogs.47,56 In the present study, no dog of the AG group
was positive for C. difficile by qPCR on day 0, whereas on day 6, 38%
of the dogs tested positive. Although, the results did not reach signifi-
cance, this finding suggests that destruction of the protective intesti-
nal microbiota by amoxicillin-clavulanic acid may promote the growth
of potentially pathogenic bacteria in the intestinal tract. Further stud-
ies are needed to evaluate the role of antibiotics in the emergence of
larger numbers of C. difficile in dogs and cats.
The third goal of the study was to evaluate the impact of
amoxicillin-clavulanic acid on the amount of amoxicillin-resistant fecal
E. coli. This bacterial strain was chosen as a marker species because
98% to 99% of dogs harbor E. coli in their intestines.57,58 Although
E. coli are normal commensal bacteria in the canine intestinal tract and
most strains are nonpathogenic, E. coli is frequently found in urinary
tract infections and has the ability to cause wound infections.59 Every
dog in our study treated with amoxicillin-clavulanic acid for 6 days
developed significant populations of amoxicillin-resistant E. coli. In
most dogs even 100% of their E. coli had developed resistance. This is
in line with recent investigations showing that amoxicillin-resistant
E. coli can be detected in 20.2% to 78.0% of individuals treated with
this potentiated penicillin derivates.60,61 Antibiotics can have a mar-
ked effect on the development of antimicrobial-resistant isolates.62,63
Most bacterial clones are killed or the growth stops under antimicro-
bial therapy; however, there are invariably nonsusceptible subpopula-
tions that survive the antimicrobial challenge, because of intrinsic and
acquired antimicrobial resistance or both.64 These resistant isolates
then flourish, because of reduced competition from susceptible
strains. Antimicrobial-resistant bacterial strains can not only compli-
cate infections in individuals harboring these bacteria, they can also
be transmitted, directly or indirectly, to other animals and humans.
Antimicrobial resistance genes—sometimes several at once—can also
be transferred to other bacterial species via plasmids, transposable
elements or phages.65 Resistant bacterial strains can complicate infec-
tions in individuals harboring these bacteria (eg, ascending E. coli cysti-
tis during antibiotic treatment) and can spread into the environment
and affect other otherwise healthy individuals. In this context, E. coli is
only a marker species and it must be assumed that many other bacte-
rial groups respond to the selection pressure of antimicrobial treat-
ment in a similar way. Veterinarians must be aware of their effect on
the global emergence of drug-resistant infections by prescribing
broad-spectrum antibiotics in dogs with uncomplicated disease, espe-
cially when indication for antibiotic treatment is lacking.
Moreover, amoxicillin-resistant E. coli could still be isolated from
dogs treated with antibiotics 21 days after treatment. This emphasizes
that the intestinal tract acts as a reservoir for resistant bacteria long
after treatment has been stopped. Different studies suggest that high
levels of resistance genes can still be found up to 4 years after antibi-
otic exposure.66,67 This emphasizes once more the importance of pru-
dent antimicrobial usage in order to prevent spread of antibiotic
resistance.
There are limitations of the study. First of all, owners gave the
treatments at home. Although owners were trained in administering
the capsules according to the schedule and to report if capsule admin-
istration was not possible, it cannot be completely ruled out that on
some occasions, treatments were not administered. Moreover, clinical
disease activity of dogs was scored by the owner themselves.
Although some variables included in scores that can be objectively
assessed (eg, defecation frequency, fecal consistency based on fecal
scoring system), some variables (eg, activity) are relatively subjective.
Clinical impression also depends on the time spent with the dog,
which differs between owners. Moreover, all enrolled dogs are from
the same geographical region, which makes generalization impossible.
Furthermore, complete fecal microbiota sequencing was not per-
formed. Therefore, for the purpose of the microbiome analysis it can-
not be ruled out that a different method would have been able to
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detect changes in the composition of the intestinal microbiome
between dogs treated with and without amoxicillin-clavulanic acid.
No specific mechanism of resistance was investigated in this study.
The main limitation of this study is the small number of dogs in both
treatment groups. Sample-size calculation was based on clinician's
opinion, because comparable studies were lacking at the time when
the study-protocol was designed. It is impossible to make clear recom-
mendations based on the present study alone. Together with other
published data, the present study should make a contribution toward
setting up guidelines on the usage of antimicrobials in AD. However,
the difference in development of bacterial resistance to amoxicillin
was very clear and statistically significant and all dogs improved clini-
cally within the study period. Thus, it seems unlikely that the results
would have changed significantly with a larger group.
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